SimBioSys

About

SimBioSys is a TechBio company based in Chicago, Illinois, founded in 2018. It specializes in computational oncology, utilizing artificial intelligence and biophysical modeling to enhance precision medicine in cancer care. The company has secured $21.7 million in funding from notable investors, including AV8 Ventures and Mayo Clinic. One of SimBioSys's key offerings is PhenoScope™, a platform that integrates multi-modal data analysis to expedite oncology drug development. This platform utilizes a vast dataset of over 12,000 patient profiles and a virtual tumor bank of more than 20,000 spatially resolved tumors. The company also provides predictive analytics for personalized patient responses, optimizing drug binding and dosing to improve therapeutic outcomes. Additionally, SimBioSys supports virtual trials, which help reduce development timelines and costs while enhancing the safety and efficacy of therapies. SimBioSys collaborates with various partners to advance oncology drug development, targeting pharmaceutical companies, healthcare providers, and researchers. Its mission is to personalize cancer care, bridging the gap between drug development and clinical practice to improve patient outcomes.